Logo image of MBAV

M3-BRIGADE ACQUISITION V-A (MBAV) Stock Fundamental Analysis

NASDAQ:MBAV - KYG632121078 - Common Stock

10.55 USD
-0.03 (-0.28%)
Last: 8/22/2025, 8:22:07 PM
Fundamental Rating

1

MBAV gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. MBAV has a bad profitability rating. Also its financial health evaluation is rather negative. MBAV is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MBAV was profitable.
MBAV had a negative operating cash flow in the past year.
MBAV Yearly Net Income VS EBIT VS OCF VS FCFMBAV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 0 1M 2M 3M 4M 5M

1.2 Ratios

Industry RankSector Rank
ROA 3.44%
ROE 3.62%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MBAV Yearly ROA, ROE, ROICMBAV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 0 0.5 1 1.5

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MBAV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MBAV Yearly Profit, Operating, Gross MarginsMBAV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

There is no outstanding debt for MBAV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MBAV Yearly Shares OutstandingMBAV Yearly Shares OutstandingYearly Shares Outstanding 2024 10M 20M 30M
MBAV Yearly Total Debt VS Total AssetsMBAV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2024 50M 100M 150M 200M 250M

2.2 Solvency

MBAV has an Altman-Z score of 15.04. This indicates that MBAV is financially healthy and has little risk of bankruptcy at the moment.
MBAV has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 15.04
ROIC/WACCN/A
WACCN/A
MBAV Yearly LT Debt VS Equity VS FCFMBAV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

A Current Ratio of 0.62 indicates that MBAV may have some problems paying its short term obligations.
MBAV has a Quick Ratio of 0.62. This is a bad value and indicates that MBAV is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.62
Quick Ratio 0.62
MBAV Yearly Current Assets VS Current LiabilitesMBAV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2024 200K 400K 600K 800K 1M

More info and screens

0

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5627.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MBAV is valuated quite expensively with a Price/Earnings ratio of 36.38.
When comparing the Price/Earnings ratio of MBAV to the average of the S&P500 Index (27.24), we can say MBAV is valued slightly more expensively.
Industry RankSector Rank
PE 36.38
Fwd PE N/A
MBAV Price Earnings VS Forward Price EarningsMBAV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MBAV Per share dataMBAV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

MBAV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

M3-BRIGADE ACQUISITION V-A

NASDAQ:MBAV (8/22/2025, 8:22:07 PM)

10.55

-0.03 (-0.28%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)08-14 2025-08-14
Earnings (Next)N/A N/A
Inst Owners101.97%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap379.17M
AnalystsN/A
Price TargetN/A
Short Float %0.19%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 36.38
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.32
P/tB 1.32
EV/EBITDA N/A
EPS(TTM)0.29
EY2.75%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS7.98
TBVpS7.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.44%
ROE 3.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.62
Quick Ratio 0.62
Altman-Z 15.04
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5627.27%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A